Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Phase 2 N=78 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Phase 2 N=148 Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Carcinoma of Urinary Tract · Urethral Carcinoma · Carcinoma of Ureter
Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months
Phase 2 N=17 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Phase 3 N=1,004 A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Urinary Tract Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Phase 2 N=51 Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Myeloproliferative Disorder · Urothelial Carcinoma · Cancer
Primary: Evaluate the Time to Disease Progression — 6.5; 13.9 months
Phase 2 N=19 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
N/A N=24 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
Phase 2 N=22 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Phase 2 N=13 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=46 Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Bladder Cancer · Metastatic Transitional Cell Carcinoma
Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants
Phase 2 N=17 Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Recurrent Bladder Cancer · Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants
Phase 2 N=14 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Urothelial Carcinoma
Primary: Overall Response Rate — 11 Participants
Phase 2 N=26 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Urothelial Carcinoma
Primary: Objective Response Rate — 8.3 Percentage of participants
Phase 2 N=36 Gemzar, Cisp, Sunitinib Urothelial Ca
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Phase 2 N=39 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants
Phase 2 N=66 Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma
Primary: Overall Response Rate (ORR) — 48.5 Percentage of patients with response
Phase 2 N=15 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants
Phase 2 N=22 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Phase 2 N=42 Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
Urologic Neoplasms
Primary: Number of Participants With Progression-free Survival at Six Months (PFS6) in Cohort A — 4 Participants
Phase 3 N=84 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 21.4; 9.5 percentage of participants
Phase 2 N=17 Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Bladder Cancer
Primary: Progression Free Survival (PFS) — 9.5 months
Phase 2 N=13 A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
Urinary Tract Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 92.3 percentage of participants
N/A N=20 Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection
Cancer of the Urinary Tract
Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants
Phase 2 N=39 Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma With Sarcomatoid Features
Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants
Phase 2 N=87 Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
Metastatic Bladder Urothelial Carcinoma · Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Metastatic Ureter Urothelial Carcinoma
Primary: Progression-free Survival (PFS) — 8.0; 8.0 Months